Get access

Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma

Authors

  • K. Batschinski,

    Corresponding author
    1. Veterinary Medical Center, Center for Comparative Oncology, Michigan State University, East Lansing, MI, USA
    • Correspondence address:

      Dr K. Batschinski

      Veterinary Medical Center

      Center for Comparative Oncology

      Michigan State University

      736 Wilson Road

      East Lansing, MI 48842, USA

      e-mail: batska@cvm.msu.edu

    Search for more papers by this author
  • N. G. Dervisis,

    1. Veterinary Medical Center, Center for Comparative Oncology, Michigan State University, East Lansing, MI, USA
    Search for more papers by this author
  • B. E. Kitchell

    1. Veterinary Medical Center, Center for Comparative Oncology, Michigan State University, East Lansing, MI, USA
    Search for more papers by this author

Abstract

A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA). Dogs diagnosed with OSA and previously treated with standard chemotherapy were included in the study. Nineteen dogs met the inclusion criteria, and 17 dogs were evaluable for response. Ifosfamide doses ranged from 375 to 425 mg m−2 (median dose 375 mg m−2), with a median of two doses administered per dog (range 1–7 doses). The overall response to ifosfamide was 11.8% [complete response (CR) = 1/17, partial response (PR) = 1/17, stable disease (SD) = 2/17, progressive disease (PD) = 13/17]. Two dogs were hospitalized due to ifosfamide toxicosis. The median survival duration from the first dose of ifosfamide to death was 95 days. Ifosfamide was well tolerated, but minor anti-tumour activity was observed.

Ancillary